These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9365453)

  • 1. Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin.
    Gottlieb JJ; Washenik K; Chachoua A; Friedman-Kien A
    Lancet; 1997 Nov; 350(9088):1363-4. PubMed ID: 9365453
    [No Abstract]   [Full Text] [Related]  

  • 2. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.
    Coukell AJ; Spencer CM
    Drugs; 1997 Mar; 53(3):520-38. PubMed ID: 9074848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal doxorubicin: new preparation. Useful in Kaposi's sarcoma.
    Prescrire Int; 1998 Jun; 7(35):69-70. PubMed ID: 10342919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma.
    Amantea MA; Forrest A; Northfelt DW; Mamelok R
    Clin Pharmacol Ther; 1997 Mar; 61(3):301-11. PubMed ID: 9084455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete remission of a case of classical Kaposi's sarcoma with liposomal doxorubicin and radiotherapy.
    Ezquerra GM; Redonnet MS; Cuchillero RO; Millet PU
    J Eur Acad Dermatol Venereol; 2006 Aug; 20(7):901-2. PubMed ID: 16898935
    [No Abstract]   [Full Text] [Related]  

  • 6. Liposomal drug targeting in the treatment of Kaposi's sarcoma.
    Wernz JC
    AIDS Patient Care STDS; 1996 Dec; 10(6):362-7. PubMed ID: 11361553
    [No Abstract]   [Full Text] [Related]  

  • 7. Liposomal doxorubicin (Doxil).
    Porche DJ
    J Assoc Nurses AIDS Care; 1996; 7(2):55-9. PubMed ID: 8679968
    [No Abstract]   [Full Text] [Related]  

  • 8. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma.
    Northfelt DW; Martin FJ; Working P; Volberding PA; Russell J; Newman M; Amantea MA; Kaplan LD
    J Clin Pharmacol; 1996 Jan; 36(1):55-63. PubMed ID: 8932544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma.
    Hjortsberg C; Persson U; Lidbrink E; Bennett C
    Acta Oncol; 1999; 38(8):1063-7. PubMed ID: 10665764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of liposomal daunorubicin and its use in Kaposi's sarcoma.
    Chew T; Jacobs M
    Oncology (Williston Park); 1996 Jun; 10(6 Suppl):28-33; discussion 37-8. PubMed ID: 16871707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
    Lichterfeld M; Qurishi N; Hoffmann C; Hochdorfer B; Brockmeyer NH; Arasteh K; Mauss S; Rockstroh JK;
    Infection; 2005 Jun; 33(3):140-7. PubMed ID: 15940415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin.
    Castiñeiras I; Almagro M; Rodríguez-Lozano J; Fernández-Jorge B; Paradela S; Pozo JD; Fonseca E
    J Dermatolog Treat; 2006; 17(6):377-80. PubMed ID: 17853313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal-doxorubicin in human immunodeficiency virus-associated Kaposi's sarcoma.
    Poizot-Martin I; Giovannini M; Rosello R; Viallat JR; Sauniere JF; Dalmas AM; Genre D; Dhiver C; Gastaut JA
    J Clin Oncol; 1994 Mar; 12(3):645. PubMed ID: 8120565
    [No Abstract]   [Full Text] [Related]  

  • 14. Kaposi's sarcoma: DaunoXome approved.
    AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel for treating KS.
    Proj Inf Perspect; 1997 Nov; (23):15. PubMed ID: 11365372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma.
    White RM
    AIDS; 1997 Sep; 11(11):1412-3. PubMed ID: 9302461
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA approves KS drug. Food and Drug Administration. Florida Department of Health and Rehabilitation Services.
    AIDS Alert; 1996 Jan; 11(1):11-2. PubMed ID: 11363227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal daunorubicin marketed for HIV-related Kaposi's sarcoma.
    Am J Health Syst Pharm; 1996 Jul; 53(13):1500, 1505. PubMed ID: 8809269
    [No Abstract]   [Full Text] [Related]  

  • 19. Low to moderate cumulative doses of pegylated liposomal doxorubicin in the treatment of classic Kaposi sarcoma in elderly patients with comorbidities.
    Potouridou I; Korfitis C; Ioannidou D; Polydorou D; Zakopoulou N; Stratigos AJ; Katsambas AD
    Br J Dermatol; 2008 Feb; 158(2):431-2. PubMed ID: 18067475
    [No Abstract]   [Full Text] [Related]  

  • 20. Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma.
    Grange C; Geninatti-Crich S; Esposito G; Alberti D; Tei L; Bussolati B; Aime S; Camussi G
    Cancer Res; 2010 Mar; 70(6):2180-90. PubMed ID: 20215497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.